Pfizer, Inc. (NYSE:PFE) shares are slightly higher on Thursday after the European Commission approved Pfizer's DURVEQTIX.
Pfizer announced Thursday that the European Commission approved a conditional marketing authorization for DURVEQTIX, a gene therapy for severe and moderately severe hemophilia B in adults whom meet certain criteria.
Hemophilia B is a rare genetic disorder that impairs blood clotting due to a deficiency in Factor IX, leading individuals with the condition to experience more frequent and prolonged bleeding.
"DURVEQTIX has shown the potential to offer long-term bleed protection in a one-time dose, reducing or eliminating bleeds for the appropriate patients with hemophilia B. These outcomes and their impact could become potentially transformative for hemophilia B care in the European Union," said chief international commercial officer and executive vice president at Pfizer Alexandre de Germay.
DURVEQTIX is already approved in the United States and Canada.
For the 2024 fiscal year second quarter, analyst estimates an EPS of 46 cents and revenue of $13.02 billion.
Related Link: GOP Strategist Asks Republicans To Challenge Joe Biden On Drug Pricing: 'Go After It'
PFE Price Action: At the time of writing, Pfizer shares are trading 1.55% higher $30.45 per data from Benzinga Pro.
Image: Photo via Shutterstock